Date: 2017-02-21
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Lanthio Pharma, Morphosys ' subsidiary (The Netherlands)
Product: MOR107 (formerly LP2)
Action
mechanism: peptide/lanthipeptide. MOR107 is a lanthipeptide based on Lanthio Pharma's proprietary technology platform. The compound is a selective agonist of the angiotensin II receptor type 2 with potential to treat diabetic nephropathy and fibrotic diseases. Lanthipeptides are cyclical peptide molecules which have been engineered with the intention to achieve enhanced stability and selectivity. This novel class of therapeutics has been developed by the Dutch biopharmaceutical company Lanthio Pharma Pharma. Morphosys has acquired the company in May 2015.
Disease:
Therapeutic area:
Country: UK
Trial details:
Latest
news: *On February 21, 2017, MorphoSys's subsidiary Lanthio Pharma has initiated a phase 1 clinical study with MOR107. The goal of the trial is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered single ascending doses (SAD) of MOR107 in healthy male volunteers. The randomized, double-blind, placebo-controlled phase 1 study will be conducted in a single center in the United Kingdom and will enroll 80-110 subjects. Topline results of the study are expected in the second half of 2017.
